Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Drug Delivery Companies Set their Sights on Higher Revenues with Novel Ocular Drug Delivery Methods - Participants in the U.S. ocular drug delivery market are all set to experience a spurt in revenue activity, since the highest rates of serious ocular disease prevalence are among the aged, who comprise the fastest growing population segment in the US
Drug Delivery Companies Set their Sights on Higher Revenues with Novel Ocular Drug Delivery Methods

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2008/12/11 - Participants in the U.S. ocular drug delivery market are all set to experience a spurt in revenue activity, since the highest rates of serious ocular disease prevalence are among the aged, who comprise the fastest growing population segment in the US.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This statistic has highlighted the need for more effective ophthalmics, encouraging research in innovative ocular drug delivery methods.

New analysis from Frost & Sullivan (pharma.frost.com), U.S. Ocular Drug Delivery Market, finds that the market earned revenues of $4.74 billion in 2007 and estimates this to reach $7.56 billion in 2012.

If you are interested in a virtual brochure, which provides manufacturers, end-users, and other industry participants with an overview of the U.S. ocular drug delivery market, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you via email.

While ease-of-use is one of the primary factors that drug manufacturers consider when catering to this demographic, they are also investing significant funds for developing extended release formulations with increased bioavailability.

“Advancements in formulation technologies could lead to novel drugs, more efficacious reformulations of existing therapies, and reduced toxicities due to novel delivery mechanisms,” explains Frost & Sullivan Research Analyst Misty Hughes. “While topical administration will remain a mainstay in the treatment of most ocular disorders, sustained release formulations or devices to achieve optimum therapeutic drug levels will boost research in this area.”

The R&D process, however, involves lengthy and costly clinical trials, which often impede endeavors to introduce new products. Market entrants not only have limited funds for conducting clinical trials, but are also challenged to find patients willing to participate in them.

Pharmaceutical and biotechnology companies will be eager to find solutions to such market barriers since effective lifecycle management and a strong pipeline are vital to their success. Therefore, it is crucial for companies to seek out mutually beneficial research partnerships.

“Smaller drug delivery and formulation companies must seek out lucrative licensing and development partnerships with larger companies to defray the costs of bringing a drug to market,” notes Hughes. “Through such collaborations, smaller companies receive the funding and human capital they need to facilitate the development of their technologies and compounds, while large companies proactively manage their pipelines by keeping a broad portfolio of potential new products.”

Market participants need to rely on direct-to-consumer (DTC) marketing to drive home the extensive benefits that new formulations offer – including new treatment regimens requiring fewer, less-invasive administrations – to expand customer base and revenue growth.

“There are many public awareness initiatives such as ‘Raising America's Eye-Q’, aimed at general education regarding age-related macular degeneration (AMD),” observes Hughes. “EyeCare America provides awareness about particularly serious conditions as well as facilitates access to medical eye exams and treatment for up to one year at no cost for eligible seniors.”

U.S. Ocular Drug Delivery Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Service program, which also includes research in the following markets: South African ophthalmology pharmaceuticals market, U.S. leading ophthalmic diseases market, and U.S. therapeutic monoclonal antibodies markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Drug Delivery Companies Set their Sights on Higher Revenues with Novel Ocular Drug Delivery Methods

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com

Visit  JobsWare.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today